Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA1 or HA2 peptide vaccination after allogeneic stem cell transplantation for advanced hematological malignancies
ISRCTN11974092Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Nov 2008
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of HA1 peptide vaccine and HA2 peptide vaccine in hematopoietic malignancies and leukemia (3 arms), sponsored by Hannover Medical School. Primary endpoint: Toxicity of immunisation. Started Nov 2008; status: completed.
02
Drugs
HA1 peptide vaccineHA2 peptide vaccine
03
Conditions
hematopoietic malignanciesleukemia
Beyond the preview
Go deeper on ISRCTN11974092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11974092.